Shots:
- Mabwell has dosed its first patient with Bulumtatug Fuvedotin (BFv or 9MW2821) in P-I trial for the treatment of TNBC pts
- Trial will assess safety & efficacy of BFv in TNBC pts previously treated with a taxane & an ADC with a topoisomerase inhibitor payload, measuring ORR as the 1EP
- Bulumtatug Fuvedotin, a Nectin-4–targeting ADC developed using Mabwell’s IDDC platform, has advanced into P-III trials for urothelial carcinoma as monotx. or in combination with a PD-1 inhibitor, & for cervical cancer
Ref: Mabwell | Image: Mabwell | Press Release
Related News:- Mabwell Signs Licensing Agreement with Qilu Pharmaceutical for Albipagrastim Alfa Injection Technology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
